Alpha Cognition Stock
Alpha Cognition Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael E. McFadden
- Employees
- 71
- Market cap
- $127 M
- IPO
- 12/11/2024
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical…
Alpha Cognition stock: price history
1D
-3.1%
1W
-9.4%
1M
-2.5%
6M
+18.0%
YTD
+26.0%
1Y
+16.0%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~102% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Alpha Cognition
Analyst assessment of Alpha Cognition
PRICE TARGET LOW
US$12.00
CONSENSUS
US$17.25
MEDIAN
US$18.50
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 17/08/2026
Alpha Cognition stock metrics
P/E
-7.5
P/B
3.37
EV/EBITDA
-3.12
RETURN ON EQUITY
-16.6%
NET MARGIN
-144.3%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.2%
FLOAT SHARES
11,218,889
AVG. DAILY VOLUME (30D)
101,826
Insider transactions (SEC)
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Alpha Cognition stock
What does Alpha Cognition do?
Alpha Cognition Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael E. McFadden, the company employs around 71 people.
The IPO was on 12/11/2024; the stock trades on NASDAQ under the ticker ACOG.
What do analysts say about Alpha Cognition stock?
1 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$17.25, ranging from US$12.00 to US$20.00, with a median of US$18.50.
This is an external assessment, not a statement by Market Jury.
When does Alpha Cognition report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 102% stronger than usual.
Does Alpha Cognition pay a dividend?
No, Alpha Cognition currently does not pay a dividend.
Which stocks are comparable to Alpha Cognition?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Alpha Cognition stock analyzed?
Clicking "Analyze stock" lets five strategies assess Alpha Cognition against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.